Skip to main content
ArticleOPEN ACCESS

Tigit checkpoint inhibition for myeloma

Blood
DOI: 10.1182/blood-2018-08-864231
9Citations
Citations of this article
31Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

In this issue of Blood, 2 companion papers by Guillerey et al1 and Minnie et al2 investigate mechanisms underlying immune effector dysfunction in myeloma and highlight T-cell immunoglobulin and ITIM domains (TIGIT) blockade as a novel checkpoint inhibition strategy.

Cite

CITATION STYLE

APA

Asimakopoulos, F. (2018, October 18). Tigit checkpoint inhibition for myeloma. Blood. American Society of Hematology. https://doi.org/10.1182/blood-2018-08-864231

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free